<DOC>
	<DOCNO>NCT02795546</DOCNO>
	<brief_summary>The aim present study evaluate bone formation potential 400µg alendronate deliver β-TCP treatment periodontal intra-osseous defect .</brief_summary>
	<brief_title>Effect Alendronate With β - TCP Bone Substitute Surgical Therapy Periodontal Intra-osseous Defects .</brief_title>
	<detailed_description>The aim present study evaluate bone formation potential 400µg alendronate ( ALN ) deliver β-TCP treatment periodontal intra-osseous defect . Materials Methods : Thirty patient periodontal defect randomly assign 400µg ALN + β-TCP + saline ( test ) group β-TCP + saline ( active-control ) group . Clinical parameter like clinical attachment level ( CAL ) gain , probe depth ( PD ) reduction , post-operative gingival recession ( GR ) assess baseline , 3 month 6 month recording . Radiographic parameter like linear bone growth ( LBG ) , percentage bone fill ( % BF ) , change alveolar crest height ( ACH ) assess baseline 6 month radiograph .</detailed_description>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Systemically healthy patient intraosseous defect probe depth ≥ 7mm baseline , presence ≥ 4mm vertical interproximal bone defect least one bony wall surgical debridement history previous periodontal therapy include study Patients know systemic disease , aggressive periodontitis , smoke habit , know suspect allergy bisphosphonates , pregnant lactate woman , study tooth exhibit tooth mobility great grade II class III furcation defect exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>periodontal regeneration</keyword>
</DOC>